Kelly A. Birdwell, M.D., M.S.C.I.
Vanderbilt University Medical Center
(View Abstract)
Kelly Birdwell is an assistant professor of medicine at Vanderbilt University Medical Center. She received her M.D. from Emory University and her M.S. in clinical investigation from Vanderbilt University. Birdwell is a physician-scientist dedicated to improving long-term outcomes in kidney transplantation, with a focus on understanding and reducing the cardiovascular disease that is the primary cause of death with a functioning graft in this population. She conducts clinical research in kidney transplant recipients, with studies on tacrolimus pharmacogenomics and on metabolic complications of transplantation and immunosuppressive drugs. Through her Translational Scholar Career Award in Pharmacogenomics and Personalized Medicine, she is using a DNA biobank and the electronic medical record system to perform genetic association studies of the drug tacrolimus with new onset diabetes after transplant, with the ultimate goal of understanding an individual’s risk of metabolic complications while taking certain immunosuppressants. Birdwell aims to become an expertly trained, independent physician scientist in transplant pharmacogenomics, using large patient-oriented research studies in kidney transplant recipients to bring personalized medicine to clinical practice.
Supported by: NCRR (prior to 2012)/NCATS.
Jerry Ingrande, M.D., M.S.
Stanford University School of Medicine
(View Abstract)
Jerry Ingrande is an instructor of anesthesia and department head of bariatric anesthesia at Stanford University. Ingrande completed a fellowship in clinical pharmacology, pharmacokinetics and pharmacodynamics, and has M.S. degrees in applied physiology and epidemiology. His research interests include studying the effects of obesity on anesthetic drug distribution, metabolism, elimination and drug response. He is using his Translational Scholar Career Award in Phamacogenomics and Personalized Medicine to examine the effect of insulin resistance and adipokine gene and protein expression on the pharmacokinetics and pharmacodynamics of anesthetic drugs in obese subjects.
Supported by: NCRR (prior to 2012)/NCATS.
Joseph P. Kitzmiller, M.D., Ph.D., F.C.P.
The Ohio State University Medical Center
(View Abstract)
Joseph Kitzmiller is an assistant professor and co-director of the Clinical Pharmacology Fellowship Program at the Ohio State University Medical Center. He is a clinical supervisor and consultant at Ohio Clinical Trials and a primary-care physician with the Ohio Association of Free Clinics. Kitzmiller received an M.D. degree and graduate degrees in biomedical engineering and pharmacology from Ohio State University. He completed postdoctoral training in both internal medicine and clinical pharmacology, and is a board-certified clinical pharmacologist (American Board of Clinical Pharmacology) and a certified physician investigator with the Association of Pharmaceutical Physician Investigators. His primary research effort involves investigating genetic influence on cardiovascular disease and on how patients metabolize and respond to statin pharmacotherapy. He is developing a multi-gene pharmacokinetic-pharmacodynamic model and aims to better predict statin response.
Supported by: NCRR (prior to 2012)/NCATS.
Joshua P. Lewis, Ph.D.
University of Maryland
(View Abstract)
Joshua Lewis is an assistant professor of medicine at the University of Maryland. He received a Ph.D. in molecular genetics and genomics from Wake Forest University. The goal of his research is to identify and functionally characterize genes contributing to cardiovascular disease risk in order to ultimately translate genetic discoveries into individualized patient care through pharmacogenomics and/or other clinical approaches. He is using his Translational Scholar Career Award in Pharmacogenomics and Personalized Medicine to investigate the genetic underpinnings and mechanisms underlying aspirin and clopidogrel resistance as well as determining optimal antiplatelet dosing. Lewis’ honors include an NIH Extramural Clinical Research LRP Award, a Trainee Research Award from the American Society of Human Genetics, and a Training Fellowship in Cardiovascular Cell Biology from the National Heart, Lung, and Blood Institute.
Supported by: NIGMS.
Tracy L. McGregor, M.D., M.S.C.I.
Vanderbilt University Medical Center
(View Abstract)
Tracy McGregor is an assistant professor of pediatrics at Vanderbilt University Medical Center. She earned her B.S. from the University of Notre Dame and her M.D. from Washington University in St. Louis. She has also completed the Master of Science in Clinical Investigation program at Vanderbilt. She is a board certified pediatrician and clinical geneticist who is conducting translational research in the area of pediatric pharmacogenetics. McGregor is using her Translational Scholar Career Award in Pharmacogenomics and Personalized Medicine award to investigate the role of MTRNR1 mutations in aminoglycoside induced neonatal hearing loss. In parallel, she studies the perceptions and attitudes of families regarding pharmacogenetics in the pediatric population.
Supported by: NICHD.
Peter H. O’Donnell, M.D.
University of Chicago
(View Abstract)
Peter O’Donnell is a practicing oncologist and translational researcher with advanced training in pharmacology and pharmacogenomics. He received his undergraduate degree from the University of Notre Dame, and his M.D. from the University of Chicago. His research interests center on the discovery and implementation of pharmacogenomic findings to better individualize care. He is using his Translational Scholar Career Award in Pharmacogenomics and Personalized Medicine to lead “The 1200 Patients Project," a clinical study exploring a preemptive medical system model for personalized care that makes relevant pharmacogenomic information instantaneously accessible at the time of prescribing. This project is examining how the availability of pharmacogenomic results may improve prescribing behaviors and thereby decrease the use of inappropriate or high risk medications. O’Donnell’s honors include being a past recipient of an American Society of Clinical Pharmacology and Therapeutics Presidential Training Award, and an American Association of Cancer Researchers Future Leaders in Translational Medicine Award.
Supported by: NIGMS.
Stuart A. Scott, Ph.D.
Icahn School of Medicine at Mount Sinai
Stuart Scott is an assistant professor of genetics and genomic sciences at the Icahn School of Medicine at Mount Sinai. He is certified by the American Board of Medical Genetics as assistant director of the Mount Sinai Genetic Testing Laboratory. Scott was recently a KL2 Faculty Scholar through the Mount Sinai Institutes for Translational Sciences. His research focused on using genomic approaches to identify novel genetic variants involved in clopidogrel response variability. These studies are being expanded for his Translational Scholar Career Award in Phamacogenomics and Personalized Medicine, with the overall goal of increasing the utility of genetic testing for personalized antiplatelet therapy. His other honors include the 2011 William Bowes, Jr. Award in Medical Genetics, sponsored by the Center for Personalized Genetic Medicine at Harvard Medical School, and the 2012 Dr. Harold and Golden Lamport Research Award, sponsored by the Icahn School of Medicine at Mount Sinai.
Supported by: NIGMS.